title: Overview consensus statement. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer.
authors.affiliation: Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Marc.Garnick@praecis.com
authors.forename: M B
authors.initials: MB
authors.lastname: Garnick
authors.forename: W R
authors.initials: WR
authors.lastname: Fair
authors.forename: D
authors.initials: D
authors.lastname: Bostwick
authors.forename: F
authors.initials: F
authors.lastname: Debruyne
authors.forename: J
authors.initials: J
authors.lastname: Fourcroy
authors.forename: D
authors.initials: D
authors.lastname: Grignon
authors.forename: H
authors.initials: H
authors.lastname: Porterfield
authors.forename: G
authors.initials: G
authors.lastname: Sufrin
authors.forename: B
authors.initials: B
authors.lastname: Thrasher
authors.forename: C
authors.initials: C
authors.lastname: Hart
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D011788:Quality of Life; D012107:Research Design
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen